Atypical Multiple Drug Resistance in a Human Leukemic Cell Line Selected for Resistance to Teniposide (VM-26)

Cancer Research

Volumn 47, Issue 5, 1987, Pages 1297-1301

  Danks, Mary K ^a   Yalowich, Jack C ^a   Beck, William T ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; BLEOMYCIN; DNA; DOXORUBICIN; ETOPOSIDE; ETOPOSIDE H 3; MITOXANTRONE; TENIPOSIDE; UNCLASSIFIED DRUG; VINBLASTINE; VINCRISTINE;

BLOOD AND HEMOPOIETIC SYSTEM; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CELL SELECTION; DRUG RESISTANCE; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PRIORITY JOURNAL; THERAPY;

CELL LINE; DRUG RESISTANCE; FLOW CYTOMETRY; HUMAN; LEUKEMIA, LYMPHOCYTIC; PODOPHYLLOTOXIN; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TENIPOSIDE;

EID: 0023158059     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Beck, W. T. Vinca alkaloid-resistant phenotype in cultured human leukemic lymphoblasts. Cancer Treat. Rep., 67:875-882, 1983.
2. Seeber, S., Osielca, R., Schmidt, C. G., Achterrath, W., and Crooke, S. T. In ViVO resistance towards anthracyclines, etoposide, and cis-diamminedichloroplatinum (11). Cancer Res., 42:4719-4725, 1982.
3. Louie, K. G., Hamilton, T. C., Winkler, M. A., Behrens, B. C., Tsuro, T., Klecker, R. W., McKoy, W. M., Grotzinger, K. R., Myers, C. E., Young, R. C., and Ozols, R. F. Adriamycin accumulation and metabolism in adriamycin-sensitive and resistant human ovarian cancer cell lines. Biochem. Pharmacol., 35: 467-472, 1986.
4. Skovsgaard, T. Mechanism of cross-resistance between vincristine and daunorubicin in Ehrlich ascites tumor cells. Cancer Res., 38: 4722-4727, 1978.
5. Kartner, N., Shales, M., Riordan, J. R., and Ling, V. Daunorubicin-resistant Chinese hamster ovary cells expressing multidrug resistance and a cell-surface P-glycoprotein. Cancer Res., 43: 4413-4419, 1983.
6. Yanovich, S., and Taub, R. N. Differences in daunomycin retention in sensitive and resistant P388 leukemic cells as determined by digitized video fluorescence microscopy. Cancer Res., 43: 4167-4171, 1983.
7. Inaba, M., Fujikura, R., and Sakurai, Y. Active efflux common to vincristine and daunorubicin in vincristine-resistant P388 leukemia. Biochem. Pharmacol., 30: 1863-1865, 1981.
8. Peterson, R. H. F., Meyers, M. B., Spengler, B. A., and Biedler, J. L. Alteration of plasma membrane glycopeptides and gangliosides of Chinese hamster cells accompanying development of resistance to daunorubicin and vincristine. Cancer Res., 43: 222-228, 1983.
9. Juliano, R. L., and Ling, V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta, 455: 152-162, 1976.
10. Garman, D., and Center, M. S. Alterations in cell surface membranes in Chinese hamster lung cells resistant to adriamycin. Biochem. Biophys. Res. Commun., 105: 157–163, 1982.
11. Beck, W. T., Mueller, T. J., and Tanzer, L. R. Altered surface membrane glycoproteins in Vinca alkaloid-resistant human leukemic lymphoblasts. Cancer Res., 39:2070-2076, 1979.
12. Johnson, R. K., and Howard, R. S. Development and cross-resistance characteristics of a subline of P388 leukemia resistant to 4'-(9-acridinylamino)-methanesulfon-m-anisidide. Eur. J. Clin. Oncol., 18:479-487, 1982.
13. Hill, B. T., and Whelan, R. D. H. Establishment of vincristine-resistant and vindesine-resistant lines of murine lymphoblasts in vitro and characterization of their patterns of cross-resistance and drug sensitivities. Cancer Chemother. Pharmacol., 8: 163-169, 1982.
14. Hill, B. T., and Bellamy, A. S. Establishment of an etoposide-resistant human epithelial tumour cell line in vitro: characterization of patterns of cross-resistance and drug sensitivities. Int. J. Cancer, 33: 599-608, 1984.
15. Wilkoff, L. J., and Dulmadge, E. A. Partial cross-resistance of cultured murine leukemia vincristine-resistant P388 cells to 4'-demethylepipodophyl-lotoxin ethylidene-β-D-glycoside (40823). Proc. Soc. Exp. Biol. Med., 164: 51–56, 1980.
16. Glisson, B., Gupta, R., Smallwood-Kentro, S., and Ross, W. Characterization of acquired epipodophyllotoxin resistance in a Chinese hamster ovary cell line: loss of drug-stimulated DNA cleavage activity. Cancer Res., 46: 1934–1938, 1986.
17. Gupta, R. S. Genetic, biochemical, and cross-resistance studies with mutants of Chinese hamster ovary cells resistant to the anticancer drugs, VM-26 and VP-16-213. Cancer Res., 43:1568-1574, 1983.
18. Lee, T. and Roberts, D. Selection and characterization of L1210 sublines resistant to teniposide (VM-26). Cancer Res., 44:2981-2985, 1984.
19. Pommier, Y., Schwartz, R. E., Zwelling, L. A., Kerrigan, D., Mattern, M. R., Charcosset, J. Y., Jacquemin-Sablon, A., and Kohn, K. W. Reduced formation of protein-associated DNA strand breaks in Chinese hamster cells resistant to topoisomerase II inhibitors. Cancer Res., 46:611-616, 1986.
20. Odaimi, M., Andersson, B. S., McCredie, K. B., and Beran, M. Drug sensitivity and cross-resistance of the 4'-(9-acridinylamino)methanesulfon-m-anisidide-resistant subline of HL-60 human leukemia. Cancer Res., 46: 3330-3333, 1986.
21. Danks, M. K., and Beck, W. T. Studies of resistance and cross-resistance to vincristine (VCR), VM-26 and VP-16-213 in human leukemic cells (CEM). Proc. Am. Assoc. Cancer Res., 24:1113, 1983.
22. Conter, V., and Beck, W. T. Acquisition of multiple drug resistance by CCRF-CEM cells selected for different degrees of resistance to vincristine. Cancer Treat. Rep., 68:831-839, 1984.
23. Norman, M. R., and Thompson, E. B. Characterization of a glucocorticoid-sensitive human lymphoid cell line. Cancer Res., 37:3785-3791, 1977.
24. Beck, W. T., Cirtain, M. C., Look, A. T., and Ashmun, R. A. Reversal of Vinca alkaloid resistance but not multiple drug resistance in human leukemic cells by verapamil. Cancer Res., 46: 778-784, 1986.
25. Yalowich, J. C., and Goldman, I. D. Analysis of the inhibitory effects of VP-16-213 (etoposide) and podophyllotoxin on thymidine transport and metabolism in Ehrlich ascites tumor cells in vitro. Cancer Res., 44:984-989, 1984.
26. Beck, W. T., Cirtain, M. C., and Lefko, J. L. Energy-dependent reduced drug binding as a mechanism of Vinca alkaloid resistance in human leukemic lymphoblasts. Mol. Pharmacol., 24:485-492, 1983.
27. Sinkule, J. A., and Evans, W. E. High-performance liquid chromatographic analysis of the semi-synthetic epipodophyllotoxins, teniposide (VM-26) and etoposide (VP-16) using electrochemical detection. J. Pharm. Sci., 73: 164–168, 1984.
28. Rao, C. R. Linear Statistical Inference and its Application. New York: John Wiley and Sons, 1973.
29. Zunino, F., Gambetta, R., DiMarco, A., and Zaccara, A. Interaction of daunomycin and its derivatives with DNA. Biochim. Biophys. Acta, 277: 489–498, 1972.
30. Lown, J. W., Morgan, A. R., Yen, S-F., Wang, Y-H., and Wilson, W. D. Characteristics of the binding of the anticancer agents mitoxantrone and ametantrone and related structures to deoxyribonucleic acids. Biochemistry, 24:4028-4035, 1985.
31. Povirk, L. F. Catalytic release of deoxyribonucleic acid bases by oxidation and reduction of an iron-bleomycin complex. Biochemistry, 18: 3989-3995, 1979.
32. Marshall, B., Ralph, R. K., and Hancock, R. Blocked 5'-termini in the fragments of chromosomal DNA produced in cells exposed to the antitumor drug 4'-[(9-acridinyl)-amino]methanesulphon-m-anisidide (mAMSA). Nucl. Acids Res., 11: 4251-4256, 1983.
33. Luduena, R. F., and Roach, M. C. Interaction of tubulin with drugs and alkylating agents. 2. Effects of colchicine, podophyllotoxin, and vinblastine on the alkylation of tubulin. Biochemistry, 20:4444-4450, 1981.
34. Chen, G. L., Yang, L., Rowe, T. C., Halligan, B. D., Tewey, K. M., and Liu, L. F. Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J. Biol. Chem., 259:13560-13561, 1984.
35. Nelson, E. M., Tewey, K. M., and Liu, L. F. Mechanism of antitumor drug action: poisoning of mammalian DNA topoisomerase II on DNA by 4'-(9-acridinylamino)-methanesulfon-m-anisidide. Proc. Natl. Acad. Sci. USA, 81: 1361-1365, 1984.
36. Tewey, K. M., Chen, G. L., Nelson, E. M., and Liu, L. F. Intercalative antitumor drugs interfere with breakage-reunion reaction of mammalian DNA topoisomerase II. J. Biol. Chem., 259:9182-9187, 1984.
37. Tewey, K. M., Rowe, T. C., Yang, L., Halligan, B. D., and Liu, L. F. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science (Wash. DC), 226: 466-468, 1984.
38. Inaba, M., and Sakurai, Y. Enhanced efflux of actinomycin D, vincristine, and vinblastine in adriaumycin-resistant subline of P388 leukemia. Cancer Lett, 8:111-115, 1979.
39. Hill, B. T., Whelan, R. D. H., and Bellamy, A. S. Identification of differential drug responses and mechanism(s) of resistance in vincristine-resistant cell lines developed either by exposure to the drug or to fractionated radiation. Can. Treat. Rev., 11:73-79, 1984.
40. Lee, T., and Roberts, D. Flux of teniposide across the plasma membrane of teniposide-resistant sublines of L1210 cells. Cancer Res., 44: 2986–2990, 1984.
41. Kessel, D., Wheeler, C., Chou, T-H., Howard, W. S., and Johnson, R. K. Studies on a mode of resistance to m-AMSA. Biochem. Pharmacol., 31: 3008-3010, 1982.
42. Pommier, Y., Kerrigan, D., Schwartz, R. E., Swack, J. A., and McCurdy, A. Altered DNA topoisomerase II activity in Chinese hamster cells resistant to topoisomerase II inhibitors. Cancer Res., 46:3075-3081, 1986.
43. Glisson, B., Gupta, R., Hodges, P., and Ross, W. Cross-resistance to intercalating agents in an epipodophyllotoxin-resistant Chinese hamster ovary cell line: evidence for a common intracellular target. Cancer Res., 46:1939-1942, 1986.